A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...
Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has ...
Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...
SAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing ...
EyePoint Pharmaceuticals, a biotech attempting to grab a sliver of Regeneron’s share of the degenerative eye disease market, said six-month results show its ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call.
Regeneron reported Q4 earnings on Tuesday, with revenues up 10% versus Q4 in 2023. EYLEA HD has stabilized its franchise with a modest sales growth of 1% in 2024 versus 2023. Biosimilar ...
As part of the deal, PNG has agreed to tighten foreign investment screening and block economically unviable or high-risk projects. Papua New Guinea's government has promised not to push ahead with ...
Today, a brief rundown of news involving Amgen and Regeneron, as well as updates from Valneva, Turnstone Biologics and AdvanCell that you might have missed. Pioneers like Alnylam Pharmaceuticals have ...
News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
